Valuation: Lakefront Biotherapeutics NV

Market Cap 1.48B 1.71B 1.39B 1.27B 2.4B 163B 2.43B 16.23B 6.37B 81.25B 6.41B 6.27B 270B P/E 2026 *
-10.5x
P/E 2027 * -7.96x
Enterprise Value -502M -578M -470M -430M -812M -55.09B -822M -5.5B -2.16B -27.53B -2.17B -2.12B -91.62B EV / Sales 2026 *
-35.2x
EV / Sales 2027 * -11.1x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day-1.75%
1 week-6.72%
Current month-5.78%
1 month-14.85%
3 months-8.69%
6 months-20.23%
Current year-19.71%
1 week 22.32
Extreme 22.32
23.88
1 month 22.32
Extreme 22.32
27.12
Current year 22.32
Extreme 22.32
30.72
1 year 22.32
Extreme 22.32
32.74
3 years 20
Extreme 20
39
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Director

137 0.0002%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%-6.72%-20.00%-43.07% 1.74B
+0.93%-0.63%+3.89%+14.93% 48.57B
+0.26%+2.93%+439.43%+533.80% 41.95B
-1.53%-2.25%+30.95%+7.15% 38.85B
+0.69%+2.40%+10.48%+63.05% 37.24B
+2.47%+8.33%+15.16%+48.37% 30.67B
-0.47%+1.16%+35.93%+126.09% 16.41B
+2.31%-0.49% - - 16.1B
+0.29%+1.87%+8.17%+18.60% 13.97B
-1.43%-2.63%+3.70%-36.38% 12.62B
Average +0.18%-0.40%+58.63%+81.39% 25.81B
Weighted average by Cap. +0.43%+0.18%+88.40%+119.91%

Financials

2026 *2027 *
Net sales 14.24M 16.41M 13.33M 12.2M 23.03M 1.56B 23.33M 156M 61.22M 781M 61.61M 60.27M 2.6B 46.09M 53.11M 43.16M 39.48M 74.53M 5.06B 75.5M 505M 198M 2.53B 199M 195M 8.41B
Net income -811M -934M -759M -694M -1.31B -88.99B -1.33B -8.88B -3.49B -44.46B -3.51B -3.43B -148B -238M -274M -223M -204M -385M -26.1B -390M -2.61B -1.02B -13.04B -1.03B -1.01B -43.41B
Net Debt -1.98B -2.29B -1.86B -1.7B -3.21B -218B -3.25B -21.73B -8.53B -109B -8.58B -8.39B -362B -1.99B -2.3B -1.87B -1.71B -3.22B -219B -3.27B -21.84B -8.57B -109B -8.63B -8.44B -364B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
26-08-06 €22.48 -1.75% 114,958
26-08-05 €22.88 -1.29% 89,429
26-08-04 €23.18 -1.28% 105,164
26-08-03 €23.48 -1.59% 93,899
26-07-31 €23.86 -1.00% 94,021
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
22.48EUR
Average target price
30.28EUR
Spread / Average Target
+34.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock